PCRI Publications with Full References

The publications below represent years of combined patient care coupled with clinical observation and medical writing. This collection is a highly unusual achievement in the setting of a non-profit organization that has essentially been funded by patients.

(1992-1995 representing early work on prostate cancer by Dr. Strum)

1. Epstein AL, Strum SB, Thompson LA, et al: Combined Use of Biotinylated TNT-1 and I-131 Streptavidin for the Clinical Treatment of Prostate Cancer. The Society of Nuclear Medicine 39th Annual Meeting, Los Angeles Convention Center, Los Angeles, CA. Abstract 17089. Presented June 1992.

2. Strum SB & Tisman G: Anemia of androgen deprivation (AAD) in patients receiving combination hormonal blockade: response to erythropoietin. Presented at the 6th International Symposium on Supportive Care in Cancer, Abstract O-1, New Orleans, Louisiana, March 2-5, 1994.

3. Strum SB, Leibowitz R, Koehler SC: Small cell carcinoma of the prostate (SCPC): Complete response to cyclophosphamide, doxorubicin and etoposide (CDE). Proc Am Soc Clin Oncol 13:239a, 1994.

4. Strum SB, Epstein A, Taylor C, Thompson L, and Mills, SL: Response of hormonally refractory prostate cancer (HRPC) to TNT-1 monoclonal antibody. Proc Am Soc Clin Oncol 13:239a, 1994.

5. Strum SB & Tisman G: Anemia of androgen deprivation (AAD) in patients receiving combination hormonal blockade: response to erythropoietin. Proc Am Soc Clin Oncol 13:238a, 1994.

6. Strum SB: Neoadjuvant therapy of early prostate cancer with combination hormonal blockade (CHB). Proc Am Soc Clin Oncol 13:239a, 1994.

7. Strum SB, Scholz M.C. & Strum M: Prolonged non-detectable PSA (NDPSA) in PC patients treated with androgen deprivation may allow for discontinuation of hormone blockade. International Symposium on Recent Advances in Diagnosis & Treatment of Prostate Cancer, Quebec City, September 21-23, 1995.

8. Smith J, Andriole G, Ahmann F, Nemunaitis J, Schellhammer P, Stein B, Chodak G, Kozlowski J, Kreis W, Strum S, et al: Effects of Liarozole on PSA levels in patients with relapsed Stage D prostate cancer. Proc Amer Soc Clin Oncol 15:250, 1996.

9. Scholz MC, Strum SB, McDermed JE, Tisman G, Johnson H: Prolonged non-detectable PSA (NDPSA) in patients (PTS) receiving combination hormone blockade (CHB) allows for discontinuation of androgen blockade. Abstract submitted but not accepted #1478, AUA 1997.

10. Tisman G, Strum SB, Scholz MC, et al: Computer assisted, tumor volume-based decision making in expectant management of early stage prostate cancer. Abstract submitted but not accepted #1480, AUA 1997.

11. Strum SB, McDermed JE, Scholz MC, et al: Anemia associated with androgen deprivation in prostate cancer (PC) patients on combination hormone blockade (CHB). Abstract submitted but not accepted #1481, AUA 1997.

12. Strum S, McDermed JE, Scholz MC, Tisman G, Johnson H: Anemia associated with androgen deprivation (AAAD) due to combination hormone blockade (CHB) responds to recombinant human erythropoietin (r hu-EPO). Poster presentation at AUA. J Urol 157:232A 1997.

13. Strum S, McDermed J, Scholz M, et al: Time to non-detectable (TTND) PSA in prostate cancer (PC) patients on combination hormone blockade (CHB) predicts favorable outcomes. Proc Amer Soc Clin Oncol 16: 345a, 1997.

14. Strum SB, McDermed JE, Scholz MC, et al: Anemia associated with androgen deprivation (AAAD) in prostate cancer (PC) patients (PTS) receiving combination hormone blockade (CHB). Proc Amer Soc Clin Oncol 16:345a, 1997.

15. Tisman, G, Strum SB, Scholz MC, et al: Pre-therapy prediction of the duration of post-therapy non-detectable PSA for prostate cancer patients considering intermittent combine hormonal blockade. Proc Amer Soc Clin Oncol 16: 346a, 1997.

16. Strum SB & Scholz MC: Intermittent hormone blockade (IHB) in prostate cancer (PC) patients: Duration of non-detectable PSA (NDPSA) on androgen blockade relates to time off treatment. Abstract, 7th International Congress on Anti-Cancer Treatment, February 3-6, Paris, France, 1997.

17. Strum SB, McDermed JE, Scholz MC, et al: Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79: 933-41, 1997.

18. Strum S.: Consultation and patient information on the Internet: the patient's forum. Br J Urol 80: 22-6, 1997.
1998

19. Strum SB, Scholz MC & McDermed JE: The androgen deprivation syndrome: the incidence and severity in prostate cancer patients receiving hormone blockade. Accepted for poster presentation at the ASCO meeting May 19th, 1998, Los Angeles, CA. Proc Amer Soc Clin Oncol. 17: 316A, 1998.

20. Strum SB, and Scholz MC: Intermittent hormone blockade: optimal induction duration and predictive factors for prolonged time off hormone blockade. Accepted for oral presentation at the ASCO meeting May 19th, 1998, Los Angeles, CA., Proc Amer Soc Clin Oncol. 17: 313A, 1998.

21. Scholz MC, Strum SB, McDermed JE: A Phase II trial of Taxotere (t)/estramustine (e) combination in patients (pts) with prostate cancer (pc). Proc Amer Soc Clin Oncol. 17: 342A, 1998.

22. Strum SB, Scholz MC, and McDermed JE: Intermittent Hormone Blockade (IHB): Optimal Induction And Predictive Factors For Prolonged Time Off Hormone Blockade (HB). Prostate Cancer Research Institute. Xth International Congress on Hormonal Steroids, Quebec City, June 17-21, page 118, 1998.

23. Strum SB, Scholz MC, and McDermed JE: Combined hormone blockade (CHB) induction and finasteride maintenance (FM) permits discontinuation of CHB for prolonged periods in patients with low-volume (LV) prostate cancer (PC). The Prostate Cancer Research Institute. Xth International Congress on Hormonal Steroids, Quebec City, June 17-21, page 120, 1998.

24. Lindberg P, Strum S, Madsen L, McDermed J: Predictors of prolonged time off intermittent androgen deprivation (lAD) for prostate cancer (PC): attainment and maintenance of an undetectable PSA (UD-PSA) for 1 year or more and low volume disease (LVD). Proc Amer Soc Clin Onco 18:1333A, 1999.

25. Scholz M, Strum S, Madsen L, McDermed J: Intermittent androgen deprivation (IAD) therapy for prostate cancer (PC): PSA response on cycle 1 (C1) can predict response on subsequent cycles. Proc Amer Soc Clin Oncol 18:352A, 1999.

26. Strum S, McDermed J, Madsen L, Scholz M: Intermittent androgen deprivation (lAD) with finasteride (F) given during the induction and maintenance periods results in prolonged time off lAD in patients with localized prostate cancer (LPC). Oral presentation at ASCO. Proc Amer Soc Clin Oncol 18:353A, 1999.

27. Scholz M, Strum S, McDermed J: Intermittent androgen deprivation (IAD) with finasteride (F) during induction and maintenance permits prolonged time off IAD in localized prostate cancer (LPC). Oral presentation at AUA. J Urol 161:600A, 1999.

28. Scholz M, Strum S: Re: recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernosal injections of alprostadil: results of a prospective, randomized trial. J Urol 161:1914-5, 1999.

29. Strum SB, Scholz M, McDermed J, McCulloch M, Eliaz I: Modified citrus pectin slows PSA doubling time: a pilot clinical trial. Presented at the International Conference on Diet and Prevention of Cancer. Tampere, Finland. May 28-June 2, 1999.

30. Scholz MC, Strum SB: Re: Prostate Specific Antigen: a decade of discovery-what we have learned and where are we going. Comments on article by Polascik TJ, Oesterling JE and Partin AW in J Urol 162:293-306, 1999.

31. Strum SB, McDermed JE, Scholz MC: Intermittent hormone blockade: optimal induction duration and predictive factors for prolonged time off hormone blockade. Oncologist 5:45-52, 2000.

32. Strum SB, McDermed JE: Prostate cancer, early to advanced disease in: Life Extension Disease Prevention and Treatment. Scientific protocols that integrate mainstream and alternative medicine. Pages 554-618, January 2000.

33. Scholz M, Strum S, Mittelman P: High-dose ketoconazole and hydrocortisone (Keto) for hormone refractory prostate cancer (HRPC). Proc Amer Soc Clin Oncol 19:370a, 2000.

34. Seltzer MA, Strum SB, Scholz MC, et al: Comparison of whole body C-11 acetate and FDG PET in patients with prostate cancer. J Nuc Med 41:142, 2000.

35. Scholz MC, Guess B, Barrios F, Strum S, Leibowitz R: Low-dose single-agent weekly docetaxel (Taxotere) is effective and well tolerated in elderly men with prostate cancer. Proc Amer Soc Clin Oncol 20:173b, 2001.

Prostate Cancer Research Institute (PCRI)
 

Material provided by PCRI is intended for educational purposes for discussion with your physician and should not be considered as medical advice. Information and opinions expressed on this website are not an endorsement by PCRI for any treatment, product or service.